188813-05-0

Basic information

• Product Name: 3-BROMO-5-CHLORO-BENZALDEHYDE
• Synonyms: 3-BROMO-5-CHLORO-BENZALDEHYDE;3-Bromo-5-chlorobenzladehyde;5-Chloro-3-bromobenzaldehyde;3-BroMo-5-chlorobenzaldehyde, 98%+
• CAS NO: 188813-05-0
• Molecular Formula: C₇H₄BrClO
• Molecular Weight: 219.46
• Product Categories: C7Chemical Synthesis;Aldehydes;Carbonyl Compounds;New Products for Chemical Synthesis;Organic Building Blocks
• Mol File: 188813-05-0.mol

Chemical Properties

• Melting Point: 68-73 °C
• Boiling Point: 264.044 °C at 760 mmHg
• Flash Point: 113.49 °C
• Appearance: white crystal powder
• Density: 1.698 g/cm³
• Vapor Pressure: 0.01mmHg at 25°C
• Refractive Index: 1.623
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• CAS DataBase Reference: 3-BROMO-5-CHLORO-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-CHLORO-BENZALDEHYDE(188813-05-0)
• EPA Substance Registry System: 3-BROMO-5-CHLORO-BENZALDEHYDE(188813-05-0)

Safety Data

• Hazard Codes: Xn,N
• Statements: 36/37/38-51/53-22
• Safety Statements: 26-36/37/39-61-53
• RIDADR: UN 3077 9/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 188813-05-0(Hazardous Substances Data)

Usage

Chemical Properties

white crystal powder

InChI:InChI=1/C7H4BrClO/c8-6-1-5(4-10)2-7(9)3-6/h1-4H

Synthetic route

1,3-dibromo-5-chlorobenzene (14862-52-3) + N,N-dimethyl-formamide (68-12-2, 33513-42-7) → 3-bromo-5-chloro-benzaldehyde (188813-05-0)

Conditions	Yield
Stage #1: 1,3-dibromo-5-chlorobenzene With n-butyllithium In hexane; di-isopropyl ether at -78℃; for 0.5h; Inert atmosphere; Stage #2: N,N-dimethyl-formamide In hexane; di-isopropyl ether at -78℃; Inert atmosphere;	67%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + ethylene glycol (107-21-1) → 2-(3-chloro-5-formylphenyl)-2-methylpropanenitrile (230642-94-1)

Conditions	Yield
With toluene-4-sulfonic acid In toluene Inert atmosphere; Reflux;	100%
With toluene-4-sulfonic acid In toluene for 18h; Heating / reflux; Water removal;	85%
With toluene-4-sulfonic acid In toluene for 6h; Reflux; Dean-Stark;	6.05 g
With toluene-4-sulfonic acid In toluene at 140℃; for 2h; Inert atmosphere;

3-bromo-5-chloro-benzaldehyde (188813-05-0) + aniline (62-53-3) → C13H9BrClN

Conditions	Yield
In toluene at 111℃; for 18h; Inert atmosphere;	93%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + 9-phenanthrenylboronic acid (68572-87-2) → C21H13ClO

Conditions	Yield
With tetrakis(triphenylphosphine) palladium(0); potassium carbonate In tetrahydrofuran; water for 12h; Inert atmosphere; Reflux;	90%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + benzamidine monohydrochloride (1670-14-0) → 2-(3-bromo-5-chlorophenyl )-4,6-diphenyl-1,3,5-triazine (1073062-42-6)

Conditions	Yield
Stage #1: 3-bromo-5-chloro-benzaldehyde; benzamidine monohydrochloride With potassium phosphate In dimethyl sulfoxide at 90℃; for 1h; Stage #2: With magnesium sulfate; 2,3-dicyano-5,6-dichloro-p-benzoquinone In tetrahydrofuran; dimethyl sulfoxide at 20℃; for 0.166667h;	87%

biphenyl-4-acetaldehyde (92-91-1) + 3-bromo-5-chloro-benzaldehyde (188813-05-0) → C21H14BrClO

Conditions	Yield
With sodium methylate In ethanol for 5h;	80%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + trimethyl orthoformate (149-73-5) → 1-bromo-3-chloro-5-(dimethoxymethyl)benzene

Conditions	Yield
With toluene-4-sulfonic acid In methanol for 12h; Reflux;	78%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + acetophenone (98-86-2) → C15H10BrClO

Conditions	Yield
With sodium methylate In methanol; ethanol for 5h;	77%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + 1-t-Butoxycarbonylpiperazine (57260-71-6) → 4-(3-bromo-5-chloro-benzyl)piperazine-1-carboxylic acid tert-butyl ester (1460033-73-1)

Conditions	Yield
With sodium tris(acetoxy)borohydride; triethylamine In dichloromethane at 20℃; for 16h;	76%

2-thioxo-4-thiazolidinone (141-84-4) + 3-bromo-5-chloro-benzaldehyde (188813-05-0) → 5-(3-bromo-5-chlorobenzylidene)-2-thioxothiazolidin-4-one

Conditions	Yield
With sodium hydroxide In ethanol Reflux;	75%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + ((1-bromo-3-chloro-naphthalene-7-yl)methyl)triphenylphosphonium bromide → 1-bromo-7-(2-(3-bromo-5-chlorophenyl)vinyl)-3-chloronaphthalene

Conditions	Yield
Stage #1: ((1-bromo-3-chloro-naphthalene-7-yl)methyl)triphenylphosphonium bromide With potassium tert-butylate In tetrahydrofuran for 5h; Inert atmosphere; Reflux; Stage #2: 3-bromo-5-chloro-benzaldehyde In tetrahydrofuran at 0 - 20℃; for 12h;	70%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + ((1-bromo-4-chloro-naphthalene-7-yl)methyl)triphenylphosphonium bromide → 4-bromo-6-(2-(5-bromo-3-chlorophenyl)vinyl)-1-chloronaphthalene

Conditions	Yield
Stage #1: ((1-bromo-4-chloro-naphthalene-7-yl)methyl)triphenylphosphonium bromide With potassium tert-butylate In tetrahydrofuran for 5h; Inert atmosphere; Reflux; Stage #2: 3-bromo-5-chloro-benzaldehyde In tetrahydrofuran at 0 - 20℃; for 12h; Inert atmosphere; Reflux;	67%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + bis(pinacol)diborane (73183-34-3) → 3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde

Conditions	Yield
With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; palladium diacetate In 1,4-dioxane for 12h; Reflux;	63%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + (6-bromopyridin-2-yl)boronic acid (440680-34-2) → 3-(6-bromopyridin-2-yl)-5-chlorobenzaldehyde

Conditions	Yield
With tetrakis(triphenylphosphine) palladium(0); potassium carbonate In tetrahydrofuran; water for 24h; Reflux;	62%
With tetrakis(triphenylphosphine) palladium(0); potassium carbonate In tetrahydrofuran; water for 24h; Reflux;	62%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + C23H19N3 → C30H19BrClN3

Conditions	Yield
Stage #1: 3-bromo-5-chloro-benzaldehyde; C23H19N3 In ethanol at 20℃; for 0.5h; Stage #2: With [bis(acetoxy)iodo]benzene In ethanol at 20℃; for 3h;	61%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + 1,8-diazaspiro[4.5]decane-8-carboxylic acid tert butyl ester (937729-06-1) → tert-butyl 1-(3-bromo-5-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Conditions	Yield
Stage #1: 3-bromo-5-chloro-benzaldehyde; 1,8-diazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester In dichloromethane at 20℃; for 2h; Molecular sieve; Inert atmosphere; Stage #2: With sodium tris(acetoxy)borohydride In dichloromethane at 20℃; Time; Molecular sieve; Inert atmosphere;	60%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + (3-bromophenyl)boronic acid (89598-96-9) → 3'-bromo-5-chloro-[1,1'-biphenyl]-3-carbaldehyde

Conditions	Yield
With tetrakis(triphenylphosphine) palladium(0); potassium carbonate In tetrahydrofuran; water for 24h; Reflux;	60%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + N-phenylpent-4-enamide (58804-62-9) → 3-chloro-5-((5-oxo-1-phenylpyrrolidin-2-yl)methyl)benzaldehyde

Conditions	Yield
With Ir(dF(CF3)ppy)2(bpy)PF6; Ni(4,4'-dimethoxy-2,2'-bipyridine)(H2O)2Br2; dibutylphosphoric acid tetrabutylammonium salt In toluene; tert-butyl alcohol at 20℃; for 48h; Inert atmosphere; Sealed tube; Irradiation;	56%

4-Methoxystyrene (637-69-4) + 3-bromo-5-chloro-benzaldehyde (188813-05-0) → (E)-3-chloro-5-(4-methoxystyryl)benzaldehyde

Conditions	Yield
With palladium diacetate; triethylamine; tris-(o-tolyl)phosphine In N,N-dimethyl acetamide at 100℃; for 16h; Inert atmosphere;	54%
With palladium diacetate; triethylamine; tris-(o-tolyl)phosphine In N,N-dimethyl acetamide at 100℃; for 16h;	54%

morpholine (110-91-8) + 3-bromo-5-chloro-benzaldehyde (188813-05-0) → 3-chloro-5-morpholinobenzaldehyde (1446818-81-0)

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl In toluene at 90℃; Inert atmosphere;	52%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + potassium ((4-(tert-butoxycarbonyl)piperidin-1-yl)methyl)trifluoroborate → tert-butyl 1-(3-chloro-5-formylbenzyl)piperidine-4-carboxylate

Conditions	Yield
With palladium diacetate; caesium carbonate; XPhos In tetrahydrofuran; water at 80℃; Inert atmosphere;	47%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + p-aminoethylbenzoate (94-09-7) → 4-{[1-(3-bromo-5-chloro-phenyl)-methylidene]-amino}-benzoic acid ethyl ester (1343455-97-9)

Conditions	Yield
In ethanol for 2h; Reflux;	35%
In ethanol for 2h; Reflux;	35%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (141449-85-6) → tert-butyl 5-(3-chloro-5-formylphenyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl In toluene at 80℃; Inert atmosphere;	32%

3-bromo-5-chloro-benzaldehyde (188813-05-0) + malonic acid (141-82-2) → ClBrC6H3CH(NH2)CH2COOH

Conditions	Yield
With ammonium acetate In isopropyl alcohol Heating;

3-bromo-5-chloro-benzaldehyde (188813-05-0) → ClBrC6H3CH(NH2)CH2COOC2H5

Conditions	Yield
Multi-step reaction with 2 steps 1: ammonium acetate / propan-2-ol / Heating 2: HCl View Scheme

3-bromo-5-chloro-benzaldehyde (188813-05-0) → ClBrC6H3CH(NH2)CH2COOC2H5 (792907-29-0)

Conditions	Yield
Multi-step reaction with 3 steps 1: ammonium acetate / propan-2-ol / Heating 2: HCl 3: immobilized Pseudomonas cepacia lipase / various solvent(s) / 24 h / 20 °C View Scheme

3-bromo-5-chloro-benzaldehyde (188813-05-0) → ClBrC6H3CH(NH2)CH2COOH

Conditions	Yield
Multi-step reaction with 3 steps 1: ammonium acetate / propan-2-ol / Heating 2: HCl 3: immobilized Pseudomonas cepacia lipase / various solvent(s) / 24 h / 20 °C View Scheme

3-bromo-5-chloro-benzaldehyde (188813-05-0) → C22H22ClBrFN5O5C2H4

Conditions	Yield
Multi-step reaction with 4 steps 1.1: ammonium acetate / propan-2-ol / Heating 2.1: HCl 3.1: immobilized Pseudomonas cepacia lipase / various solvent(s) / 24 h / 20 °C 4.1: isobutyl chloroformate; N-methylmorpholine / N,N-dimethyl-acetamide / 0.25 h / 5 - 20 °C 4.2: N-methylmorpholine / N,N-dimethyl-acetamide / 20 °C View Scheme

3-bromo-5-chloro-benzaldehyde (188813-05-0) → C22H22ClBrFN5O5

Conditions	Yield
Multi-step reaction with 5 steps 1.1: ammonium acetate / propan-2-ol / Heating 2.1: HCl 3.1: immobilized Pseudomonas cepacia lipase / various solvent(s) / 24 h / 20 °C 4.1: isobutyl chloroformate; N-methylmorpholine / N,N-dimethyl-acetamide / 0.25 h / 5 - 20 °C 4.2: N-methylmorpholine / N,N-dimethyl-acetamide / 20 °C 5.1: aq. NaOH / acetonitrile / 3 h / 20 °C View Scheme

Upstream product

• 14862-52-3 1,3-dibromo-5-chlorobenzene 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1229245-70-8 N-[(3-bromo-5-chlorophenyl)methyl]cyclopropanamine 
• 1343455-98-0 2-(3-bromo-5-chloro-phenyl)-4-hydroxy-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid ethyl ester 
• 1343456-00-7 2-(3-bromo-5-chloro-phenyl)-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid ethyl ester 
• 1343456-71-2 2-(3-fluoro-5-piperazin-1-yl-phenyl)-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid 
• 1541198-81-5 (S)-ethyl 3-amino-3-(3-chloro-5-(2-hydroxypropan-2-yl)phenyl)propanoate hydrochloride 
• 1541197-94-7 C₁₄H₁₇ClO₄ 
• 1541197-95-8 C₁₃H₁₇ClO₃ 
• 1541197-96-9 C₁₄H₁₉ClO₃ 
• 1446818-81-0 3-chloro-5-morpholinobenzaldehyde 
• 1073062-42-6 2-(3-bromo-5-chlorophenyl )-4,6-diphenyl-1,3,5-triazine 

Relevant articles and documents

BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, whereinA ispharmaceutical compositions thereof and methods of using such compounds and compositions as alphavbeta3 antagonists.